­
medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2022, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2022; 38 (3)

Risk of viral post-transplant complications in living donor kidney transplant candidates

Marcell RL, Costales ED, Morera BLM, Chang MA

Language: Spanish
References: 41
Page: 1-10
PDF size: 533.96 Kb.


ABSTRACT

Introduction: Living donor kidney transplant is promoted in our country and the rest of the world. The definition of Cytomegalovirus (CMV) and Epstein Barr virus (EBV) post-transplant complications risk is part of pretransplant compatibility tests.
Objective: To assess post-transplant complication risk with these viruses in Cuban candidates to living donor kidney transplant.
Methods: Detection of IgG anti-CMV and IgG anti-EBV antibodies by enzyme-linked immunoabsorbent assay was performed on 301 receptors and 390 living donors’ serum examples received, from July 2013 to July 2019, at the Histocompatibility department of the Institute of Hematology and Immunology.
Results: In candidates to living donor kidney transplant, EBV seroprevalence was greater than CMV’s and increased with age. The 100% of AB blood group had CMV and EBV. There was no association between IgG anti-CMV and IgG anti-EBV antibodies and anti-HLA antibodies, age, gender, skin color, blood group, hepatitis B and C, dialysis type, previous transplants, and transfusions. The 7.3% of patients were labeled as post-transplant complications high risk.
Conclusions: The seroprevalence of CMV and EBV in living donor kidney transplant Cuban candidates is high, that´s why patients with high risk for post-transplant complications due to these viruses are a few.


REFERENCES

  1. Villafuerte-Ledesma HM, De Sousa-Amorim E, Peri L, Musquera M, Palou E, Lozano M, et al1. . Impact of Discards for Living Donor Kidney Transplantation in a Transplant Program. Transplant Proc. 2019;51(10):3222-6.DOI: https:// 10.1016/j.transproceed.2019.09.008

  2. Kaya B, Erturk D, Paydas S, Demir E, Balal M, Gocum H. Evaluation of Living Kidney Donor and Recipient Candidates: The Experience of Our Center. Transplant Proc. 2019;51(7):2205-9. DOI: https:// 10.1016/j.transproceed.2019.04.071

  3. Valdivia-Arencibia J, Gutiérrez-Gutiérrez C, Méndez-Felipe D, Delgado-Almora E, Treto-Ramírez J, Fernández-Maderos I. Supervivencia en pacientes con trasplante renal. Factores pronósticos. Invest Medico quir. 2013;5(2):253-75.

  4. Marcell-Rodríguez L, Núñez-Gómez M, Morera-Barrios LM, Bencomo-Hernández A, ChangMonteagudo A, Ustariz-García C Caracterización de los anticuerpos anti-HLA en receptores de trasplante renal de donante vivo relacionado. Rev Cubana Hematol Inmunol Hemoter 2017;33(S1) [acceso 04/02/2022] Disponible en: Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/759 4.

  5. Marcell Rodríguez L, Morera Barrios LM, Costales Elizalde DT, Chang Monteagudo A, Ustariz García C, Bencomo Hernández A Anticuerpos anticitomegalovirus y antivirus de Epstein Barr pretrasplante renal en Cuba. Rev Cubana Hematol Inmunol Hemoter. 2016;32(4) [acceso 04/02/22]. Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/4635.

  6. Pretagostini R, Poli L, Lai Q, Russo G, Nudo F, Garofalo M, et al6. . Pre-Emptive Therapy for the Treatment of Cytomegalovirus After Kidney Transplantation. Transplant Proc. 2017;49(4):638-41. DOI: https:// 10.1016/j.transproceed.2017.02.019

  7. Parajuli S, Muth BL, Turk JA, Astor BC, Mohammed M, Mandelbrot DA, et al7. . In Kidney Transplant Recipients with a Positive Virtual Crossmatch, High PRA was Associated With Lower Incidence of Viral Infections. Transplantation. 2016;100(3):655-61. DOI: https:// 10.1097/tp.0000000000001061

  8. Costales Elizalde D, Morera Barrios LM, González García N, Chang Monteagudo A, Marcell Rodríguez L, Ustariz García CR, et al8. . Anticuerpos anticitomegalovirus y antivirus de Epstein Barr en pacientes cubanos en espera de trasplante hematopoyético. Rev Cubana Hematol Inmunol Hemoter 2017;33:1-9. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892017000200011&nrm=iso8.

  9. Babazadeh A, Javanian M, Oliaei F, Akbari R, Akbarzadepasha A, Bijani A, et al9. . Incidence and risk factors for cytomegalovirus in kidney transplant patients in Babol, northern Iran. Caspian J Intern Med. 2017;8(1):23-9. PMID: 28503279.

  10. Chang PY, Chien LN, Lin YF, Wu MS, Chiu WT, Chiou HY. Risk factors of gender for renal progression in patients with early chronic kidney disease. Medicine(Baltimore). 2016;95(30):e4203. DOI: https:// 10.1097/md.0000000000004203

  11. Kazancioğlu R. Risk factors for chronic kidney disease: an update. Kidney Int Suppl (2011). 2013;3(4):368-71. DOI: https:// 10.1038/kisup.2013.70

  12. Sentell T, Choi SY, Ching L, Quensell M, Keliikoa LB, Corriveau É, et al12. . Prevalence of Selected Chronic Conditions Among Children, Adolescents, and Young Adults in Acute Care Settings in Hawai'i. Prev Chronic Dis. 2020;17:E67. DOI: https:// 10.5888/pcd17.190448

  13. Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle Factors, Obesity and the Risk of Chronic Kidney Disease. Epidemiology. 2003;14(4):479-87. DOI: https:// 10.1097/01.EDE.0000071413.55296.c4

  14. Andersson C, Vasan RS. Epidemiology of cardiovascular disease in young individuals. Nat Rev Cardiol. 2018;15(4):230-40. DOI: https:// 10.1038/nrcardio.2017.154

  15. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet2017;389:1238-52. DOI: https:// 10.1016/S0140-6736(16)32064-5

  16. Hounkpatin HO, Fraser SDS, Honney R, Dreyer G, Brettle A, Roderick PJ. Ethnic minority disparities in progression and mortality of pre-dialysis chronic kidney disease: a systematic scoping review. BMC Nephrology. 2020;21(1):217. DOI: https:// 10.1186/s12882-020-01852-3

  17. Morera Barrios LM, Chang Monteagudo A, García García MdA, de la Guardia O, Ustariz García C, Marcell Rodriguez L, et al17. . Frecuencia de genes HLA en pacientes con insuficiencia renal crónica procedentes del occidente y centro de Cuba. Rev Cubana Hematol Inmunol Hemoter 2015;31:32-40. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892015000100004&nrm=iso17.

  18. Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, et al18. . Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. Rev Med Virol. 2019;29(3):e2034. DOI: https:// 10.1002/rmv.2034

  19. Fourcade G, Germi R, Guerber F, Lupo J, Baccard M, Seigneurin A, et al. Evolution of EBV seroprevalence and primary infection age in a French hospital and a city laboratory network, 2000-2016. PLoS One. 2017;12(4):e0175574.doi:10.1371/journal.pone.0175574

  20. Kuri A, Jacobs BM, Vickaryous N, Pakpoor J, Middeldorp J, Giovannoni G, et al20. . Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom. BMC Public Health. 2020;20(1):912. DOI: https:// 10.1186/s12889-020-09049-X

  21. Farid E, Al-Biltagi M. Trend and seroprevalence of Epstein-Barr virus in Bahrain: 2001-2015. East Mediterr Health J. 2018;23(12):821-9. DOI: https:// 10.26719/2017.23.12.821

  22. Beader N, Kolarić B, Slačanac D, Tabain I, Vilibić-Čavlek T. Seroepidemiological study of Epstein-Barr virus in different population groups in Croatia. Isr Med Assoc J. 2018;20(2):86-90.Disponible en: https://www.ima.org.il/FilesUploadPublic/IMAJ/0/272/136222.pdf22.

  23. Mahmood R, Malik F, Hussain S, Ashfaq K, Akhtar T, Alam MR, et al23. . Seroprevalence of cytomegalovirus among blood donors in local population. Int J Pharm Chem 2014;4:146-50. DOI: https:// 10.7439/ijpc

  24. Varga M, Görög D, Kári D, Környei E, Kis É, Túryné HJ, et al24. . Cytomegalovirus seroprevalence among solid organ donors in Hungary: correlations with age, gender, and blood group. Transplant Proc. 2011;43(4):1233-5. DOI: https:// 10.1016/j.transproceed.2011.03.067

  25. Tiguman GMB, Poll LB, Alves CEC, Pontes GS, Silva MT, Galvao TF. Seroprevalence of cytomegalovirus and its coinfection with Epstein-Barr virus in adult residents from Manaus: a population-based study. Rev Soc Bras Med Trop. 2020;53:e20190363. DOI: https:// 10.1590/0037-8682-0363-2019

  26. Samiei RN, Mahmoudvand S, Shokri S, Makvandi M, Shahbazian H, Pirmoradi R, et al26. . The frequency of Epstein-Barr virus among hemodialysis patients, Ahvaz, Iran. Iran J Microbiol. 2019;11(1):75-9. DOI: https:// 10.18502/ijm.v11i1.709

  27. Berntsson M, Dubicanac L, Tunbäck P, Ellström A, Löwhagen GB, Bergström T. Frequent detection of cytomegalovirus and Epstein-Barr virus in cervical secretions from healthy young women. Acta Obstet Gynecol Scand. 2013;92(6):706-10. DOI: https:// 10.1111/aogs.12134

  28. Taie AA, Ibraheem MA, Fadhil KB. Epstein-barr virus infection in thalassemia patients related to blood group in Mosul / Iraq. Ann Tropical Med Public Health. 2019;22:136-45. DOI: https:// 10.36295/asro.2019.220815

  29. Guinault D, Del Bello A, Lavayssiere L, Nogier MB, Cointault O, Congy N, et al29. . Outcomes of kidney transplant recipients admitted to the intensive care unit: a retrospective study of 200 patients. BMC Anesthesiol. 2019;19(1):130. DOI: https:// 10.1186/s12871-019-0800-0

  30. D'Orsogna L, van den Heuvel H, van Kooten C, Heidt S, Claas FHJ. Infectious pathogens may trigger specific allo-HLA reactivity via multiple mechanisms. Immunogenetics. 2017;69(8-9):631-41. DOI: https:// 10.1007/s00251-017-0989-3

  31. Krishnan NS, Zehnder D, Daga S, Lowe D, Lam FT, Kashi H, et al31. . Behaviour of Non-Donor Specific Antibodies during Rapid Re-Synthesis of Donor Specific HLA Antibodies after Antibody Incompatible Renal Transplantation. PLoS One. 2013;8(7):e68663. DOI: https:// 10.1371/journal.pone.0068663

  32. Ettenger R, Chin H, Kesler K, Bridges N, Grimm P, Reed EF, et al32. . Relationship Among Viremia/Viral Infection, Alloimmunity, and Nutritional Parameters in the First Year After Pediatric Kidney Transplantation. Am J Transplant. 2017;17(6):1549-62. DOI: https:// 10.1111/ajt.14169

  33. Vilibic-Cavlek T, Kolaric B, Ljubin-Sternak S, Kos M, Kaic B, Mlinaric-Galinovic G. Prevalence and dynamics of cytomegalovirus infection among patients undergoing chronic hemodialysis. Indian J Nephrol. 2015;25(2):95-8. DOI: https:// 10.4103/0971-4065.139488

  34. Radhakrishnan R, Gopal B, Zachariah U, Abraham P, Mohapatra A, Valson A, et al34. . The long-term impact of hepatitis C infection in kidney transplantation in the pre-direct acting antiviral era. Saudi J Kidney Dis Transpl. 2018;29(5):1092-9. DOI: https:// 10.4103/1319-2442.243964

  35. Levitsky J, Doucette K. Viral hepatitis in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):147-68. DOI: https:// 10.1111/ajt.12108

  36. Liu YC, Lu PL, Hsiao HH, Chang CS, Liu TC, Yang WC, et al36. . Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus. Ann Hematol. 2012;91(4):587-95. DOI: https:// 10.1007/s00277-011-1351-8

  37. Shoman S, Nabil M, Tabl A, Ghanem H, Kafrawy SE. Assessment of immunological changes in Epstein-Barr virus co-infection in Egyptian chronic HCV patients. Mem Inst Oswaldo Cruz. 2014;109(6):722-7. DOI: https:// 10.1590/0074-0276140049

  38. Rao SC, Ashraf I, Mir F, Samiullah S, Ibdah JA, Tahan V. Dual Infection with Hepatitis B and Epstein-Barr Virus Presenting with Severe Jaundice, Coagulopathy, and Hepatitis B Virus Chronicity Outcome. Am J Case Rep. 2017;18:170-2. DOI: https:// 10.12659/ajcr.901688

  39. Sundin M, Le Blanc K, Ringdén O, Barkholt L, Omazic B, Lergin C, et al39. . The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica. 2006;91(8):1059-67.

  40. Azevedo LS, Pierrotti LC, Abdala E, Costa SF, Strabelli TM, Campos SV, et al40. . Cytomegalovirus infection in transplant recipients. Clinics (Sao Paulo). 2015;70(7):515-23. DOI: https:// 10.6061/clinics/2015(07)09

  41. Bao X, Zhu Q, Qiu H, Chen F, Xue S, Ma X, et al41. . Clinical risks analysis of EBV infection in patients with allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2016;37(2):138-43. DOI: https:// 10.3760/cma.j.issn.0253-2727.2016.02.011




2020     |     www.medigraphic.com

    Este sitio utiliza cookies   Estoy de acuerdo